This article presents an overview of Corporate Insiders Are Selling These 5 Small-Cap Stocks. For a detailed overview of such stocks, read our article, Corporate Insiders Are Selling These 10 Small-Cap Stocks.
5. Couchbase Inc (NASDAQ:BASE)
Number of Hedge Fund Investors: 19
Database software company Couchbase Inc (NASDAQ:BASE) ranks fifth in our list of the small-cap stocks insiders are selling. Couchbase Inc’s (NASDAQ:BASE) CFO Greg Henry on March 21 dumped 18,747 shares of Couchbase Inc (NASDAQ:BASE) at $27.84. Since then the stock is down about 5.18%.
Out of the 933 funds tracked by Insider Monkey, 19 hedge funds reported owning stakes in Couchbase Inc (NASDAQ:BASE) at the end of the fourth quarter of 2023, up from 12 funds in the previous quarter.
4. Ryerson Holding Corp. (NYSE:RYI)
Number of Hedge Fund Investors: 19
Industrial metals company Ryerson Holding Corp. (NYSE:RYI) is one of the small-cap stocks with latest insider selling transactions. Ryerson Holding Corp.’s (NYSE:RYI) Chief Information Office Alagu Sundarrajan dumped 6,932 shares of Ryerson Holding Corp. (NYSE:RYI) on March 22 at $32.76 per share. He also sold 2,593 shares of Ryerson Holding Corp. (NYSE:RYI) on March 25 at $32.52 a piece. Since March 22 Ryerson Holding Corp. (NYSE:RYI) shares are down 0.4%.
3. Phreesia Inc (NYSE:PHR)
Number of Hedge Fund Investors: 20
Phreesia Inc (NYSE:PHR) makes software solutions for the healthcare industry. Phreesia Inc’s (NYSE:PHR) COO Evan Roberts on March 21 unloaded 25,962 shares of Phreesia Inc (NYSE:PHR) at $23.52 per share. Since March 21 through March 26 the stock is almost flat.
Conestoga Capital Advisors Micro Cap Strategy stated the following regarding Phreesia, Inc. (NYSE:PHR) in its fourth quarter 2023 investor letter:
“Phreesia, Inc. (NYSE:PHR): PHR, a leader in patient intake software to the medical industry, had a strong rebound in the fourth quarter after being a laggard in the third quarter. PHR reported a strong third quarter, with margins and adjusted EBITDA significantly beating expectations. PHR’s management also pivoted their financial model with the introduction of their 2024 guidance, reflecting an increased focus on profitability, which came in materially ahead of expectations. Revenue growth guidance moderated but is still projected at greater than 20%.”
2. Vita Coco Company Inc (NASDAQ:COCO)
Number of Hedge Fund Investors: 23
Coconut water company Vita Coco Company Inc (NASDAQ:COCO) is one of the small-cap stocks with latest insider selling. Vita Coco Company Inc’s (NASDAQ:COCO) COO Jonathan Burth on March 12 sold 45,000 shares of Vita Coco Company Inc (NASDAQ:COCO) at $25.02 per share. Vita Coco Company Inc’s (NASDAQ:COCO) cofounder and board member Ira Liran also sold 46,303 shares of Vita Coco Company Inc (NASDAQ:COCO) on March 19 at $25.02 per share. Since then Vita Coco Company Inc (NASDAQ:COCO) shares have lost about 4.53%.
1. Mirum Pharmaceuticals Inc (NASDAQ:MIRM)
Number of Hedge Fund Investors: 33
California-based Mirum Pharmaceuticals Inc (NASDAQ:MIRM) works on treatments for rare diseases. Mirum Pharmaceuticals Inc’s (NASDAQ:MIRM) Chief Operating Officer Peter Radovich on March 25 sold 4,303 shares of Mirum Pharmaceuticals Inc (NASDAQ:MIRM) for $25.80 per share. Since this transaction the stock price has lost about 4.7% in value.
ClearBridge Small Cap Growth Strategy stated the following regarding Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in its fourth quarter 2023 investor letter:
“In the fourth quarter we initiated four new investments: Inari Medical, Blackbaud, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Installed Building Products. Mirum Pharmaceuticals is a commercial stage pharmaceutical company primarily treating rare liver conditions, often in pediatric patients. With multiple approved marketed products across different indications, the company is already operating near cash[1]flow breakeven. Mirum is pursuing label indication expansions across two of its marketed products that could be materially additive to the growth trajectory, along with two promising Phase 2 candidates designed to treat several adult rare liver diseases.”
Should you invest $1,000 in Mirum Pharma right now?
Before you buy stock in MIRM, consider this:
The Insider Monkey Quarterly Newsletter just identified what we believe are the 14 best stocks for investors to buy now… and MIRM wasn’t one of them. The 14 stocks that made the cut could produce monster returns in the next few months.
Quarterly Newsletter is your easy-to-follow blueprint for building a winning portfolio. It includes stock picks from billionaires, regular updates from hedge fund investor letters, and 14 fresh stock picks each quarter. The Quarterly Newsletter service has more than doubled the return of S&P 500 since 2014.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also look at the Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks and the 10 Mining Stocks with Heavy Insider Buying in 2024.
